Germany
Japan
United Kingdom
China
Antibodies
Rabbit Polyclonal PD-L1 Antibody
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | PD-L1 antibody was raised against a 17 amino acid synthetic peptide from near the center of human PD-L1. The immunogen is located within amino acids 60 - 110 of PD-L1. |
USD 479.00
2 Weeks
Rabbit polyclonal HAPLN1 Antibody (N-term)
| Applications | FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This HAPLN1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 10-38 amino acids from the N-terminal region of human HAPLN1. |
Rabbit polyclonal HLA-G Antibody (Center)
| Applications | FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This HLA-G antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 62-89 amino acids from the Central region of human HLA-G. |
Rabbit Polyclonal Anti-Angiotensin II Receptor Type-1 (extracellular)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide NSSTEDGIKRIQDDC, corresponding to amino acid residues 4-18 of human AT1 receptor. Extracellular, N-terminus. |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 3C2-4
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 3G11-14
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 4A5-19
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 5F4-15
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 5G12-21
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 6F5-23
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 6H8-22
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 8E8-2
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 8F6-6
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 9G5-20
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 12G4-15
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 15C4-8
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 16F12-11
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
USD 524.00
In Stock
Rabbit Polyclonal Antibody against CD19 (N-term)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This CD19 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 143-172 amino acids from the N-terminal region of human CD19. |
USD 440.00
2 Weeks
Mouse Anti-Human IL-1 beta Purified (50 ug)
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Rabbit polyclonal ROR2 Antibody (N-term)
| Applications | FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This ROR2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 19-50 amino acids from the N-terminal region of human ROR2. |
Rabbit Polyclonal Anti-KV11.1 (HERG) (extracellular)
| Applications | FC, IF, IHC, IP, WB |
| Reactivities | Human, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide AFLLKETEEGPPATEC corresponding to residues 430-445 of human KV11.1 (HERG). Extracellular, between S1 and S2 domains. |
Goat Polyclonal Anti-Vimentin Antibody
| Applications | FC, IF, WB |
| Reactivities | Human (Expected from sequence similarity: Mouse, Rat, Dog, Pig, Cow) |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for Anti-Vimentin Antibody: Peptide with sequence C-QVINETSQHHDDLE, from the C Terminus of the protein sequence according to NP_003371.2. |
Rabbit polyclonal MGMT Antibody (C-term)
| Applications | FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This MGMT antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 156-182 amino acids from the C-terminal region of human MGMT. |
Rabbit Polyclonal Anti-Serotonin Transporter (SERT) (extracellular)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide (C)EMRNEDVSEVAKD, corresponding to amino acids residues 388-400 of rat Serotonin Transporter. 4th extracellular loop. |
Rabbit polyclonal CP Antibody (Center)
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This CP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 547-577 amino acids from the Central region of human CP. |
Active filters
Applications
- FC
Conjugates
- Unconjugated
Filter by
Target Symbol
- PDCD1 (129)
- CD5 (110)
- HAVCR2 (73)
- CTAG1B (72)
- ERCC1 (69)
- PECAM1 (64)
- LIPG (63)
- CD274 (61)
- L1CAM (53)
- PDCD1LG2 (53)
- CD47 (51)
- CTNNB1 (51)
- TNFRSF8 (49)
- TP53 (48)
- CTLA4 (47)
- ERBB2 (47)
- CD33 (46)
- TIGIT (46)
- CD40 (44)
- CD99 (42)
- ICOS (42)
- LGR5 (42)
- FGF21 (39)
- LAG3 (39)
- LRATD2 (39)
- PNMT (39)
- SENP2 (39)
- CD80 (37)
- TNFRSF9 (37)
- PTPRC (36)
- SQSTM1 (36)
- AFP (35)
- CD63 (34)
- ACAT2 (33)
- MICAL1 (33)
- RNF144B (33)
- TTC32 (33)
- TTLL12 (33)
- UBE2E3 (33)
- ZFP36 (33)
- BTLA (32)
- CD2 (31)
- BTK (30)
- CD38 (30)
- CDK2 (30)
- HIBCH (30)
- IGF2BP2 (30)
- KATNB1 (30)
- LENG1 (30)
- MAPK7 (30)
- MAPRE2 (30)
- MEIS3 (30)
- MOB3B (30)
- NME4 (30)
- NPR3 (30)
- PACSIN3 (30)
- PDE4A (30)
- PFKP (30)
- PRKCE (30)
- RPN1 (30)
- SDR9C7 (30)
- SMS (30)
- TACC3 (30)
- CD27 (28)
- CD86 (28)
- ACY1 (27)
- AK5 (27)
- ARHGAP25 (27)
- BECN1 (27)
- BTN1A1 (27)
- CBWD1 (27)
- CD4 (27)
- DSTN (27)
- EPM2AIP1 (27)
- EXD1 (27)
- GSTT2 (27)
- HOXC11 (27)
- LDLRAP1 (27)
- LIMK1 (27)
- LRRC25 (27)
- NRBP1 (27)
- NT5DC1 (27)
- PDE2A (27)
- PIK3AP1 (27)
- SIRT5 (27)
- SNAP25 (27)
- SNX9 (27)
- SRR (27)
- STAT5A (27)
- TAL1 (27)
- TUBAL3 (27)
- ACY3 (24)
- AK4 (24)
- AKT1 (24)
- ARFGAP1 (24)
- ATP5F1B (24)
- CHCHD5 (24)
- CRYAB (24)
- DNAJA2 (24)
- ERCC4 (24)
Reactivities
- Human (11253)
- Mouse (6384)
- Rat (5804)
- Monkey (1310)
- Dog (993)
- Bovine (70)
- Pig (36)
- Chicken (32)
- Rabbit (27)
- Primate (25)
- Canine (23)
- Escherichia coli (15)
- Xenopus (15)
- Hamster (13)
- Sheep (13)
- Chimpanzee (12)
- Porcine (11)
- Cow (10)
- Zebrafish (7)
- Goat (6)
- Baboon (5)
- SARS-CoV-2 (5)
- Cynomolgus (4)
- Drosophila (4)
- Rhesus Monkey (4)
- C. elegans (2)
- Dengue virus (2)
- Ferret (2)
- Fish (2)
- Macaque (2)
- Marmoset (2)
- West Nile Virus (2)
- Yellow Fever Virus (2)
- Equine (1)
- Feline (1)
- Guinea Pig (1)
- Mustelid (1)
- Squirrel (1)
- Staphylococcus aureus (1)
- Yeast (1)
Antibody Hosts
Isotypes
Clonalities
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (55)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (34)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (18)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (17)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (16)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (16)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (13)
- This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (13)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (12)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (10)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (9)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (6)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG2 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- Phospho-specific (2)
- This chimeric hamster (Armenian) antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric antibody created to reduce immunogenicity during in vivo applications. (1)
- This is a chimeric mouse antibody, based on the original hamster IgG format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)
- This reformatted antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Families
- Druggable Genome (6310)
- Transmembrane (2783)
- Transcription Factors (1029)
- ES Cell Differentiation/IPS (866)
- Secreted Protein (688)
- Protease (543)
- Protein Kinase (535)
- Stem cell - Pluripotency (406)
- Adult stem cells (184)
- Phosphatase (179)
- Embryonic stem cells (115)
- P450 (96)
- GPCR (90)
- Ion Channels: Other (72)
- Stem cell relevant signaling - JAK/STAT signaling pathway (62)
- Stem cell relevant signaling - DSL/Notch pathway (60)
- Cancer stem cells (51)
- Induced pluripotent stem cells (43)
- Nuclear Hormone Receptor (32)
- Ion Channels: Potassium (20)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (17)
- Stem cell relevant signaling - Wnt Signaling pathway (7)
- Ion Channels: Cys-loop Receptors (2)
- Ion Channels: ATP Receptors (1)
Pathways
- Metabolic pathways (1336)
- Cell adhesion molecules (CAMs) (729)
- Pathways in cancer (545)
- Hematopoietic cell lineage (392)
- T cell receptor signaling pathway (364)
- MAPK signaling pathway (361)
- Cytokine-cytokine receptor interaction (332)
- Prostate cancer (271)
- Purine metabolism (268)
- Leukocyte transendothelial migration (252)
- Focal adhesion (249)
- Progesterone-mediated oocyte maturation (248)
- Toll-like receptor signaling pathway (237)
- Cell cycle (227)
- Regulation of actin cytoskeleton (225)
- Endometrial cancer (221)
- Neurotrophin signaling pathway (217)
- Chronic myeloid leukemia (214)
- Colorectal cancer (214)
- Huntington's disease (202)
- Pancreatic cancer (202)
- Insulin signaling pathway (197)
- Primary immunodeficiency (194)
- Non-small cell lung cancer (191)
- Melanoma (190)
- Adherens junction (187)
- Alzheimer's disease (187)
- Fc gamma R-mediated phagocytosis (185)
- ErbB signaling pathway (183)
- Apoptosis (182)
- Endocytosis (182)
- Jak-STAT signaling pathway (179)
- Wnt signaling pathway (177)
- Bladder cancer (171)
- Glycolysis / Gluconeogenesis (169)
- Systemic lupus erythematosus (167)
- Pathogenic Escherichia coli infection (166)
- Ubiquitin mediated proteolysis (162)
- Small cell lung cancer (160)
- B cell receptor signaling pathway (152)
- Tight junction (151)
- Autoimmune thyroid disease (150)
- Glioma (146)
- Pyruvate metabolism (139)
- Thyroid cancer (138)
- Fc epsilon RI signaling pathway (135)
- p53 signaling pathway (135)
- Nucleotide excision repair (133)
- Acute myeloid leukemia (132)
- Arginine and proline metabolism (132)
- Axon guidance (131)
- Glycerolipid metabolism (127)
- Viral myocarditis (125)
- Adipocytokine signaling pathway (122)
- Gap junction (122)
- Drug metabolism - cytochrome P450 (119)
- Parkinson's disease (118)
- Allograft rejection (117)
- Valine (117)
- Oocyte meiosis (114)
- Oxidative phosphorylation (112)
- leucine and isoleucine degradation (111)
- Metabolism of xenobiotics by cytochrome P450 (110)
- Basal cell carcinoma (105)
- Fructose and mannose metabolism (105)
- Type II diabetes mellitus (105)
- ECM-receptor interaction (102)
- Chemokine signaling pathway (101)
- Tyrosine metabolism (101)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (99)
- Renal cell carcinoma (99)
- Natural killer cell mediated cytotoxicity (95)
- Pyrimidine metabolism (92)
- Calcium signaling pathway (88)
- Glycine (88)
- serine and threonine metabolism (88)
- Graft-versus-host disease (87)
- Proteasome (87)
- Type I diabetes mellitus (87)
- GnRH signaling pathway (86)
- Amyotrophic lateral sclerosis (ALS) (85)
- mTOR signaling pathway (83)
- Glutathione metabolism (82)
- TGF-beta signaling pathway (78)
- Propanoate metabolism (77)
- Retinol metabolism (77)
- Tryptophan metabolism (76)
- Melanogenesis (74)
- beta-Alanine metabolism (69)
- Cysteine and methionine metabolism (68)
- Fatty acid metabolism (68)
- Histidine metabolism (68)
- Antigen processing and presentation (67)
- VEGF signaling pathway (67)
- Vascular smooth muscle contraction (66)
- Arachidonic acid metabolism (62)
- Epithelial cell signaling in Helicobacter pylori infection (62)
- Lysosome (61)
- Neuroactive ligand-receptor interaction (61)
- Pentose phosphate pathway (61)
- Butanoate metabolism (59)
- NOD-like receptor signaling pathway (57)
- Renin-angiotensin system (55)
- Citrate cycle (TCA cycle) (50)
- Lysine degradation (50)
- Regulation of autophagy (50)
- Complement and coagulation cascades (49)
- Nicotinate and nicotinamide metabolism (49)
- Hypertrophic cardiomyopathy (HCM) (48)
- PPAR signaling pathway (48)
- Terpenoid backbone biosynthesis (48)
- Asthma (47)
- Dilated cardiomyopathy (46)
- Glyoxylate and dicarboxylate metabolism (46)
- Linoleic acid metabolism (43)
- Amino sugar and nucleotide sugar metabolism (42)
- Starch and sucrose metabolism (42)
- Synthesis and degradation of ketone bodies (42)
- Porphyrin and chlorophyll metabolism (41)
- RIG-I-like receptor signaling pathway (40)
- Alanine (39)
- DNA replication (39)
- Long-term depression (39)
- Mismatch repair (39)
- aspartate and glutamate metabolism (39)
- Galactose metabolism (36)
- Prion diseases (36)
- RNA degradation (36)
- Cardiac muscle contraction (34)
- Vibrio cholerae infection (34)
- Caffeine metabolism (33)
- N-Glycan biosynthesis (33)
- Notch signaling pathway (33)
- Inositol phosphate metabolism (31)
- Cytosolic DNA-sensing pathway (30)
- Ascorbate and aldarate metabolism (28)
- Long-term potentiation (28)
- Maturity onset diabetes of the young (28)
- One carbon pool by folate (28)
- Androgen and estrogen metabolism (27)
- Non-homologous end-joining (27)
- SNARE interactions in vesicular transport (27)
- Drug metabolism - other enzymes (25)
- Spliceosome (23)
- Folate biosynthesis (22)
- Cyanoamino acid metabolism (21)
- Homologous recombination (21)
- Selenoamino acid metabolism (21)
- Sulfur metabolism (21)
- Base excision repair (20)
- Phosphatidylinositol signaling system (19)
- Pantothenate and CoA biosynthesis (18)
- Basal transcription factors (14)
- Phenylalanine metabolism (14)
- ABC transporters (13)
- Aminoacyl-tRNA biosynthesis (13)
- Glycosaminoglycan degradation (13)
- Glycerophospholipid metabolism (12)
- Hedgehog signaling pathway (12)
- RNA polymerase (12)
- Vitamin B6 metabolism (12)
- Biosynthesis of unsaturated fatty acids (11)
- Nitrogen metabolism (11)
- Dorso-ventral axis formation (10)
- Circadian rhythm - mammal (9)
- Methane metabolism (9)
- Riboflavin metabolism (9)
- Thiamine metabolism (9)
- Limonene and pinene degradation (8)
- Other glycan degradation (8)
- Sphingolipid metabolism (8)
- Pentose and glucuronate interconversions (6)
- leucine and isoleucine biosynthesis (6)
- Glycosphingolipid biosynthesis - lacto and neolacto series (4)
- Steroid biosynthesis (4)
- Biotin metabolism (3)
- C21-Steroid hormone metabolism (3)
- Glycosphingolipid biosynthesis - ganglio series (3)
- Keratan sulfate biosynthesis (3)
- Olfactory transduction (3)
- Primary bile acid biosynthesis (2)
- Taste transduction (2)
- D-Glutamine and D-glutamate metabolism (1)
- Ether lipid metabolism (1)
- Fatty acid biosynthesis (1)
- Fatty acid elongation in mitochondria (1)
- Heparan sulfate biosynthesis (1)
- Phenylalanine (1)
- Ribosome (1)
- alpha-Linolenic acid metabolism (1)
- tyrosine and tryptophan biosynthesis (1)